Markup of:

H.R. 1691, the “Ensuring Patient Access to Critical Breakthrough Products Act of 2023”

• H.R. 1691, the “Ensuring Patient Access to Critical Breakthrough Products Act of 2023”
• Amendment in the Nature of a Substitute to H.R. 1691, the “Ensuring Patient Access to Critical Breakthrough Products Act of 2023”
• Ways and Means Description of the Amendment in the Nature of a Substitute to H.R. 1691, the “Ensuring Patient Access to Critical Breakthrough Products Act of 2023” (Green Sheet)
• Amendment in the Nature of a Substitute to H.R. 1691, the “Ensuring Patient Access to Critical Breakthrough Products Act of 2023” passed by voice vote (with a quorum being present).
• H.R. 1691, the “Ensuring Patient Access to Critical Breakthrough Products Act of 2023” was ordered favorably reported to the House of Representatives as amended by an Amendment in the Nature of a Substitute, offered by Chairman Smith, by a roll call vote of 36 yeas and 5 nays.

H.R. 2407, the “Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act”

• H.R. 2407, the “Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act”
• Amendment in the Nature of a Substitute to H.R. 2407, the “Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act”
• Ways and Means Description of the Amendment in the Nature of a Substitute to H.R. 2407, the “Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act” (Green Sheet)
• Amendment in the Nature of a Substitute to H.R. 2407, the “Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act” passed by voice vote (with a quorum being present).
• H.R. 2407, the “Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act” ” was ordered favorably reported to the House of Representatives as amended by an Amendment in the Nature of a Substitute, offered by Chairman Smith, by a roll call vote of 38 yeas and 0 nays.

H.R. 8816, the “American Medical Innovation and Investment Act”

• H.R. 8816, the “American Medical Innovation and Investment Act”
• Amendment in the Nature of a Substitute to H.R. 8816, the “American Medical Innovation and Investment Act”
• Ways and Means Description of the Amendment in the Nature of a Substitute to H.R. 8816, the “American Medical Innovation and Investment Act” (Green Sheet)
• Amendment in the Nature of a Substitute to H.R. 8816, the “American Medical Innovation and Investment Act” passed by voice vote (with a quorum being present).
  1. Amendment filed by Rep. Chu was withdrawn.
• H.R. 8816, the “American Medical Innovation and Investment Act” was ordered favorably reported to the House of Representatives as amended by an Amendment in the Nature of a Substitute, offered by Chairman Smith, by a roll call vote of 40 yeas and 0 nays.

H.R. 4818, the “Treat and Reduce Obesity Act of 2023”

• H.R. 4818, the “Treat and Reduce Obesity Act of 2023”
• Amendment in the Nature of a Substitute to H.R. 4818, the “Treat and Reduce Obesity Act of 2023”
• Ways and Means Description of the Amendment in the Nature of a Substitute to H.R. 4818, the “Treat and Reduce Obesity Act of 2023” (Green Sheet)
• Amendment in the Nature of a Substitute to H.R. 4818, the “Treat and Reduce Obesity Act of 2023” passed by voice vote (with a quorum being present).
  1. Amendment filed by Rep. Doggett was not agreed to by a roll call vote of 17 yeas and 23 nays.
  2. Amendment filed by Rep. Schneider was not agreed to by a roll call vote of 15 yeas, 22 nays, and 1 present.
  3. Amendment filed by Rep. Beyer was not agreed to by a roll call vote of 17 yeas and 21 nays.
• H.R. 4818, the “Treat and Reduce Obesity Act of 2023” was ordered favorably reported to the House of Representatives as amended by an Amendment in the Nature of a Substitute, offered by Chairman Smith, by a roll call vote of 36 yeas and 4 nays.